Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

Trial Profile

A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAM-RA
  • Sponsors Amgen

Most Recent Events

  • 24 Oct 2022 Results(n=253) assessing patient-reported outcomes rheumatoid arthritis following medication withdrawal and disease worsening changes in patients with published in the JCR: Journal of Clinical Rheumatology
  • 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 18 Nov 2020 Primary endpoint (Simplified Disease Activity Index (SDAI) remission ( 3.3) at week 48) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top